Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Perseus Proteomics, Inc. ( (JP:4882) ) just unveiled an announcement.
Perseus Proteomics Inc. reported its financial results for the nine months ending December 31, 2024, showing a small increase in net sales by 15.9% compared to the previous year. Despite this, the company continues to experience financial losses, with a net loss recorded. The financial position showed an increase in total assets and net assets, but the company refrained from providing a forecast for the fiscal year ending March 31, 2025, citing difficulties in making rational predictions.
More about Perseus Proteomics, Inc.
Perseus Proteomics Inc. operates within the biotechnology industry, focusing on the development and commercialization of antibody-based products and services. The company is listed on the Tokyo Stock Exchange and engages in the research and development of therapeutic antibodies.
YTD Price Performance: 3.38%
Average Trading Volume: 871,891
Technical Sentiment Consensus Rating: Sell
Current Market Cap: Yen8.56B
See more insights into 4882 stock on TipRanks’ Stock Analysis page.